RX Stock Overview
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
BioSyent Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$8.40 |
| 52 Week High | CA$9.26 |
| 52 Week Low | CA$7.03 |
| Beta | 0.93 |
| 1 Month Change | -2.67% |
| 3 Month Change | -2.33% |
| 1 Year Change | 5.00% |
| 3 Year Change | 12.75% |
| 5 Year Change | 13.51% |
| Change since IPO | 646.67% |
Recent News & Updates
BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues
Mar 22
BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045
Feb 09Recent updates
BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues
Mar 22BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045
Feb 09BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price
Apr 14BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 19Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?
Mar 17BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year
Feb 18
Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative
Jan 28BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate
Jan 07BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 17Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?
Dec 02Shareholder Returns
| RX | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -1.8% | -1.8% | -0.6% |
| 1Y | 5.0% | 50.8% | 3.9% |
Return vs Industry: RX underperformed the Canadian Pharmaceuticals industry which returned 50.8% over the past year.
Return vs Market: RX exceeded the Canadian Market which returned 3.9% over the past year.
Price Volatility
| RX volatility | |
|---|---|
| RX Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 13.9% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: RX has not had significant price volatility in the past 3 months.
Volatility Over Time: RX's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | René Goehrum | www.biosyent.com |
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
BioSyent Inc. Fundamentals Summary
| RX fundamental statistics | |
|---|---|
| Market cap | CA$97.52m |
| Earnings (TTM) | CA$6.46m |
| Revenue (TTM) | CA$31.59m |
15.1x
P/E Ratio3.1x
P/S RatioIs RX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RX income statement (TTM) | |
|---|---|
| Revenue | CA$31.59m |
| Cost of Revenue | CA$5.99m |
| Gross Profit | CA$25.60m |
| Other Expenses | CA$19.14m |
| Earnings | CA$6.46m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.56 |
| Gross Margin | 81.03% |
| Net Profit Margin | 20.45% |
| Debt/Equity Ratio | 0% |
How did RX perform over the long term?
See historical performance and comparison